- $209.92bn
- $232.60bn
- $45.81bn
- 85
- 26
- 60
- 58
REG - AstraZeneca PLC - Enhertu approved in US for 2L HER2+ breast cancer
AnnouncementREG - AstraZeneca PLC - Ultomiris NMOSD Ph. III trial met primary endpoint
AnnouncementREG - AstraZeneca PLC - Imfinzi combo granted Priority Review for BTC
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Result of AGM
AnnouncementREG - AstraZeneca PLC - AstraZeneca plans new R&D centre in Massachusetts
AnnouncementREG - AstraZeneca PLC - First quarter 2022 results
AnnouncementREG - AstraZeneca PLC - Ultomiris approved in the US for adults with gMG
AnnouncementREG - AstraZeneca PLC - Enhertu granted BTD for HER2-low breast cancer
AnnouncementREG - AstraZeneca PLC - Tremelimumab US Priority Review for Imfinzi combo
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - AstraZeneca PLC - Enhertu granted Priority Review for HER2m NSCLC
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Ondexxya approved in Japan for FXai reversal
AnnouncementREG - AstraZeneca PLC - Evusheld approved in the EU for COVID-19
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Evusheld Positive EU CHMP Opinion
AnnouncementREG - AstraZeneca PLC - Update on CALLA Phase III trial for Imfinzi
AnnouncementREG - AstraZeneca PLC - Notice of AGM
Announcement